Characterizing circulating tumor cells in breast cancer patients
Official title: Ultrasensitive BIOsensing Platform for Multiplex CELLular Protein PHEnotyping at Single-cell Level
Run by Istituti Clinici Scientifici Maugeri SpA · NCT06048835 · Data updated 2026-11-12
This study is testing a new device to collect and analyze cancer cells from the blood of breast cancer patients to help tailor treatments for them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | Women only |
| Enrollment | 80 (estimated) |
| Sponsor | Istituti Clinici Scientifici Maugeri SpA Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Pavia, Lombardy) |
| Status | Recruiting |
| Started | December 1, 2022 |
| Main results expected | September 30, 2025 |
| Study ends | December 31, 2028 |
| Registry record updated | June 23, 2026 |
| Trial ID | NCT06048835 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include female patients diagnosed with metastatic breast cancer or early-stage breast cancer who are candidates for surgery.
✕Probably not a fit
Patients with any other neoplastic disease will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to develop a novel device for isolating and characterizing circulating tumor cells (CTCs) in breast cancer patients. It will involve consecutive patients diagnosed with various types of breast cancer, including metastatic and early-stage cases, as well as a control group of healthy volunteers. Blood samples will be collected at specific time points to analyze CTCs and gather clinical information, with the goal of improving patient stratification and personalized treatment approaches. The study is set to last for 24 months, starting from December 2022.
Why it matters
Potential benefit: If successful, this study could lead to improved methods for early detection of metastasis in breast cancer patients, enhancing personalized treatment strategies.
How similar studies have gone: While there have been various approaches to CTC detection, this study's specific methodology and device development represent a novel approach in the field.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * female patients with diagnosis of metastatic breast cancer, confirmed by clinical practice staging exams. * female patients with biopsy-confirmed diagnosis of early-breast cancer candidate for primary surgery after multidisciplinary evaluation. * patients not affected by any neoplastic disease. Exclusion Criteria: * Diagnosis of any neoplastic disease
Where it's running
-
Istituti Clinici Scientifici Maugeri SpA
Pavia, Lombardy, Italy Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.